Mineralys Therapeutics, Inc. MLYS
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
In the United States, there are approximately 120 million patients with sustained elevated blood pressure (BP), or hypertension. Approximately 60 million patients are treated and over 30 million do not achieve their BP goal, with approximately 20 million having systolic BP levels greater than 140 mmHg. Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to either cardiovascular disease or stroke, respectively. Dysregulated aldosterone levels are a key factor in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in approximately 30% of patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $132.0M | $168.6M | $70.4M | $26.2M | — |
| SG&A | $38.6M | $23.8M | $14.3M | $5.2M | — |
| Total operating expenses | $170.6M | $192.4M | $84.7M | $31.5M | — |
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M | — |
| Pre-tax income | -$154.7M | — | — | — | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M | — |
| EPS, basic | -2.29 | -3.66 | -1.99 | -5.77 | — |
| EPS, diluted | -2.29 | -3.66 | -1.99 | -5.77 | — |
| Shares, diluted (wtd. avg.) | 67.7M | 48.5M | 36.2M | 5.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $172.9M | $114.1M | $49.3M | $87.7M | $10.7M |
| Total current assets | $661.4M | $205.4M | $249.1M | $112.8M | — |
| Property, plant and equipment | $38.0K | $53.0K | $0 | — | — |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M | — |
| Accounts payable | $2.0M | $479.0K | $601.0K | $1.9M | — |
| Total current liabilities | $15.1M | $14.6M | $10.5M | $8.1M | — |
| Retained earnings | -$457.2M | -$302.5M | -$124.7M | -$52.8M | — |
| Total equity | $646.7M | $191.3M | $241.2M | -$52.3M | -$22.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M | -$29.2M | — |
| Depreciation and amortisation | $59.0K | $43.0K | $0 | — | — |
| Stock-based compensation | $19.3M | $11.3M | $5.1M | $455.0K | — |
| Capital expenditure | $15.0K | $96.0K | $0 | — | — |
| Investing cash flow | -$389.8M | $115.0M | -$160.5M | -$21.8M | — |
| Financing cash flow | $591.0M | $116.1M | $203.2M | $128.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001933414-26-000056.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |